Paper36958764
Adaptation of transgene mRNA translation boosts the anticancer efficacy of oncolytic HSV1.
Hoang HD and 15 others. J Immunother Cancer, 2023. Cited by 4 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Adaptation of transgene mRNA translation boosts the anticancer efficacy of oncolytic HSV1. Papers, record 36958764. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36958764
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Adaptation of transgene mRNA translation boosts the anticancer efficacy of oncolytic HSV1.
- PubMed
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Herpesvirus 1, Human | Major topic |
| Oncolytic Viruses | Major topic |
| Animals | |
| Mice | |
| Granulocyte-Macrophage Colony-Stimulating Factor | |
| Transgenes | |
| Protein Biosynthesis |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| CIHR | Canada | PubMed |
Source PubMed
References53
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 1313912 | Effect of genomic location on expression of beta-galactosidase mRNA controlled by the herpes simplex virus type 1 UL38 promoter. | J Virol | 1992 | https://conductscience.org/library/papers/1313912 | PubMed |
| 2 | 30997392 | Oncolytic Virus-Based Cytokine Expression to Improve Immune Activity in Brain and Solid Tumors. | Mol Ther Oncolytics | 2019 | https://conductscience.org/library/papers/30997392 | PubMed |
| 3 | 21886163 | Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. | Nature | 2011 | https://conductscience.org/library/papers/21886163 | PubMed |
| 4 | 26436135 | Pediatric cancer gone viral. Part I: strategies for utilizing oncolytic herpes simplex virus-1 in children. | Mol Ther Oncolytics | 2015 | https://conductscience.org/library/papers/26436135 | PubMed |
| 5 | 15003868 | Mode of transgene expression after fusion to early or late viral genes of a conditionally replicating adenovirus via an optimized internal ribosome entry site in vitro and in vivo. | Virology | 2004 | https://conductscience.org/library/papers/15003868 | PubMed |
| 6 | 17383529 | Use of an oncolytic virus secreting GM-CSF as combined oncolytic and immunotherapy for treatment of colorectal and hepatic adenocarcinomas. | Surgery | 2007 | https://conductscience.org/library/papers/17383529 | PubMed |
| 7 | 18846111 | hnRNP A1 regulates UV-induced NF-kappaB signalling through destabilization of cIAP1 mRNA. | Cell Death Differ | 2009 | https://conductscience.org/library/papers/18846111 | PubMed |
| 8 | 8892862 | The RGG box motif of the herpes simplex virus ICP27 protein mediates an RNA-binding activity and determines in vivo methylation. | J Virol | 1996 | https://conductscience.org/library/papers/8892862 | PubMed |
| 9 | 22595793 | Expression of inhibitor of growth 4 by HSV1716 improves oncolytic potency and enhances efficacy. | Cancer Gene Ther | 2012 | https://conductscience.org/library/papers/22595793 | PubMed |
| 10 | 12595888 | ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. | Gene Ther | 2003 | https://conductscience.org/library/papers/12595888 | PubMed |
| 11 | 21602908 | High cleavage efficiency of a 2A peptide derived from porcine teschovirus-1 in human cell lines, zebrafish and mice. | PLoS One | 2011 | https://conductscience.org/library/papers/21602908 | PubMed |
| 12 | 35864254 | Intratumoral oncolytic herpes virus G47∆ for residual or recurrent glioblastoma: a phase 2 trial. | Nat Med | 2022 | https://conductscience.org/library/papers/35864254 | PubMed |
| 13 | 1846210 | Upstream promoter elements of the herpes simplex virus type 1 glycoprotein H gene. | J Virol | 1991 | https://conductscience.org/library/papers/1846210 | PubMed |
| 14 | 11020347 | Tumor growth inhibition by intratumoral inoculation of defective herpes simplex virus vectors expressing granulocyte-macrophage colony-stimulating factor. | Mol Ther | 2000 | https://conductscience.org/library/papers/11020347 | PubMed |
| 15 | 31206552 | Hidden regulation of herpes simplex virus 1 pre-mRNA splicing and polyadenylation by virally encoded immediate early gene ICP27. | PLoS Pathog | 2019 | https://conductscience.org/library/papers/31206552 | PubMed |
| 16 | 29746850 | Battling for Ribosomes: Translational Control at the Forefront of the Antiviral Response. | J Mol Biol | 2018 | https://conductscience.org/library/papers/29746850 | PubMed |
| 17 | 20436464 | Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. | Nat Biotechnol | 2010 | https://conductscience.org/library/papers/20436464 | PubMed |
| 18 | 16300675 | Functional inaccessibility of quiescent herpes simplex virus genomes. | Virol J | 2005 | https://conductscience.org/library/papers/16300675 | PubMed |
| 19 | 28676792 | Long-Read Isoform Sequencing Reveals a Hidden Complexity of the Transcriptional Landscape of Herpes Simplex Virus Type 1. | Front Microbiol | 2017 | https://conductscience.org/library/papers/28676792 | PubMed |
| 20 | 29790989 | The Galaxy platform for accessible, reproducible and collaborative biomedical analyses: 2018 update. | Nucleic Acids Res | 2018 | https://conductscience.org/library/papers/29790989 | PubMed |
Cited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42580805 | HSV-1 metabolic hijacking: Mechanisms to precision therapeutics. | Virulence | 2026 | https://conductscience.org/library/papers/42580805 | PubMed |
| 40352942 | Oncolytic viruses: a promising therapy for malignant pleural effusion and solid tumors. | Front Immunol | 2025 | https://conductscience.org/library/papers/40352942 | PubMed |
| 38325225 | The combination treatment of oncolytic adenovirus H101 with nivolumab for refractory advanced hepatocellular carcinoma: an open-label, single-arm, pilot study. | ESMO Open | 2024 | https://conductscience.org/library/papers/38325225 | PubMed |
Genes8
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CSF2 | 1437 | PubTator's text mining | https://conductscience.org/library/genes/1437 | NCBI Gene |
| EEF1A2 | 1917 | PubTator's text mining | https://conductscience.org/library/genes/1917 | NCBI Gene |
| GLB1 | 2720 | PubTator's text mining | https://conductscience.org/library/genes/2720 | NCBI Gene |
| IL1B | 3553 | PubTator's text mining | https://conductscience.org/library/genes/3553 | NCBI Gene |
| POTEF | 728378 | PubTator's text mining | https://conductscience.org/library/genes/728378 | NCBI Gene |
| PTK2B | 2185 | PubTator's text mining | https://conductscience.org/library/genes/2185 | NCBI Gene |
| RPS20 | 6224 | PubTator's text mining | https://conductscience.org/library/genes/6224 | NCBI Gene |
| TNF | 7124 | PubTator's text mining | https://conductscience.org/library/genes/7124 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36958764
GET https://conductscience.org/api/papers/v1/36958764/references?page=2